From October 1, 2023 to December 18, 2023, the company has repurchased 73,300 shares, representing 0.62% for CAD 0.62 million. With this, the company has completed the repurchase of 380,000 shares, representing 3.17% for CAD 2.89 million under the buyback announced on December 13, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 CAD | 0.00% | +0.12% | -7.70% |
Apr. 22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
Apr. 01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.70% | 72.15M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2022.